Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Profit After Tax (2016 - 2025)

Historic Profit After Tax for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$67.3 million.

  • ImmunityBio's Profit After Tax rose 2154.82% to -$67.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$348.7 million, marking a year-over-year increase of 4068.64%. This contributed to the annual value of -$413.6 million for FY2024, which is 2915.24% up from last year.
  • Per ImmunityBio's latest filing, its Profit After Tax stood at -$67.3 million for Q3 2025, which was up 2154.82% from -$92.6 million recorded in Q2 2025.
  • ImmunityBio's 5-year Profit After Tax high stood at -$59.2 million for Q4 2024, and its period low was -$233.4 million during Q4 2023.
  • Over the past 5 years, ImmunityBio's median Profit After Tax value was -$95.6 million (recorded in 2023), while the average stood at -$108.1 million.
  • As far as peak fluctuations go, ImmunityBio's Profit After Tax plummeted by 18492.78% in 2021, and later skyrocketed by 7464.63% in 2024.
  • ImmunityBio's Profit After Tax (Quarter) stood at -$91.6 million in 2021, then dropped by 18.32% to -$108.3 million in 2022, then crashed by 115.47% to -$233.4 million in 2023, then soared by 74.65% to -$59.2 million in 2024, then dropped by 13.68% to -$67.3 million in 2025.
  • Its Profit After Tax stands at -$67.3 million for Q3 2025, versus -$92.6 million for Q2 2025 and -$129.7 million for Q1 2025.